Inhibition of cyclooxygenase-2 in hematopoietic cells results in salt-sensitive hypertension

Journal of Clinical Investigation

Volumn 125, Issue 11, 2015, Pages 4281-4294

  Zhang, Ming Zhi ^a,c   Yao, Bing ^a   Wang, Yinqiu ^a   Yang, Shilin ^a   Wang, Suwan ^a   Fan, Xiaofeng ^a   Harris, Raymond C ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; SODIUM CHLORIDE COTRANSPORTER; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN C; 4-(5-(4-CHLOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL)BENZENESULFONAMIDE; CYCLOOXYGENASE 2 INHIBITOR; GP38 PROTEIN, MOUSE; ISOMERASE; MEMBRANE PROTEIN; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E SYNTHASE; PTGER4 PROTEIN, MOUSE; PTGES PROTEIN, MOUSE; PTGS2 PROTEIN, MOUSE; PYRAZOLE DERIVATIVE; SALT INTAKE; SULFONAMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR C, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CELL INFILTRATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HEMATOPOIETIC CELL; HIGH SODIUM INTAKE; HOMEOSTASIS; HYPERTENSION; LONG TERM EXPOSURE; LYMPH FLOW; LYMPHANGIOGENESIS; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SALT INTAKE; SIGNAL TRANSDUCTION; SODIUM RESTRICTION; T LYMPHOCYTE; 129 MOUSE; ANIMAL; BIOSYNTHESIS; BONE MARROW CELL; C57BL MOUSE; CHEMICALLY INDUCED; DEFICIENCY; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENETICS; KIDNEY; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PERITONEUM MACROPHAGE; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; RADIATION CHIMERA; SKIN; TOXICITY;

ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; FEMALE; HYPERTENSION; INTRAMOLECULAR OXIDOREDUCTASES; KIDNEY; LYMPHANGIOGENESIS; MACROPHAGES, PERITONEAL; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MYELOID CELLS; PHOSPHORYLATION; PROSTAGLANDIN-E SYNTHASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRAZOLES; RADIATION CHIMERA; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; SKIN; SODIUM CHLORIDE SYMPORTERS; SODIUM CHLORIDE, DIETARY; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84946780888     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI81550     Document Type: Article

References (76)

1. Kanbay M, Chen Y, Solak Y, Sanders PW. Mechanisms and consequences of salt sensitivity and dietary salt intake. Curr Opin Nephrol Hypertens. 2011;20(1):37-43.
2. Whorton A, et al. Prostaglandins and renin release. I. Stimulation of renin release from rabbit renal cortical slices by PGI2. Prostaglandins. 1977;14(6):1095-1104.
3. Francisco LJ, Osborn JL, DiBona GF. Prostaglan-dins in renin release during sodium deprivation. Am J Physiol. 1982;243(6):F537-F542.
4. Linas SL. Role of prostaglandins in renin secretion in the isolated kidney. AmJ Physiol. 1984;246(6 pt 2):F811-F818.
5. Ito S, Carretero OA, Abe K, Juncos LA, Yoshinaga K. Macula densa control of renin release and glomerular hemodynamics. Tohoku J Exp Med. 1992;166(1):27-39.
6. Ito S, Carretero OA, Abe K, Beierwaltes WH, Yoshinaga K. Effect of prostanoids on renin release from rabbit afferent arterioles with and without macula densa. Kidney Int. 1989;35(5):1138-1144.
7. Greenberg SG, Lorenz JN, He XR, Schnermann JB, Briggs JP. Effect of prostaglandin synthesis inhibition on macula densa-stimulated renin secretion. Am J Physiol. 1993;265(4 pt 2):F578-F583.
8. Needleman P, Turk J, Jakschik BA, Morrison AR, Lefkowith JB. Arachidonic acid metabolism. Annu Rev Biochem. 1986;55:69-102.
9. Cheng HF, Harris RC. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des. 2005;11(14):1795-1804.
10. Svendsen KB, Bech JN, Sorensen TB, Pedersen EB. A comparison of the effects of etodolac and ibuprofen on renal haemodynamics, tubular function, renin, vasopressin and urinary excretion of albumin and alpha-glutathione-S-transferase in healthy subjects: a placebo-controlled cross-over study. Eur J Clin Pharmacol. 2000;56(5):383-388.
11. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol. 1991;31(7):588-598.
12. Kohsaka S, et al. Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study. Atherosclerosis. 2008;196(2):926-930.
13. Hernanz R, Briones AM, Salaices M, Alonso MJ. New roles for old pathways? A circuitous relationship between reactive oxygen species and cyclo-oxygenase in hypertension. Clin Sci (Lond). 2014;126(2):111-121.
14. Yu Y, et al. Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med. 2012;4(132):132ra54.
15. Harrison DG, Marvar PJ, Titze JM. Vascular inflammatory cells in hypertension. Front Physiol. 2012;3:128.
16. Guzik TJ, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204(10):2449-2460.
17. Johnson RJ, Lanaspa MA, Gabriela Sánchez-Lozada L, Rodriguez-Iturbe B. The discovery of hypertension: evolving views on the role of the kidneys, and current hot topics. Am J Physiol Renal Physiol. 2015;308(3):F167-F178.
18. + storage in rats. Am J Physiol Renal Physiol. 2003;285(6):F1108-F1117.
19. Machnik A, et al. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med. 2009;15(5):545-552.
20. Machnik A, et al. Mononuclear phagocyte system depletion blocks interstitial tonicity-responsive enhancer binding protein/vascular endothelial growth factor C expression and induces saltsensitive hypertension in rats. Hypertension. 2010;55(3):755-761.
21. Karnezis T, Shayan R, Fox S, Achen MG, Stacker SA. The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway. Oncotarget. 2012;3(8):893-906.
22. Komhoff M, et al. Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int. 2000;57(2):414-422.
23. Yang T, Huang YG, Ye W, Hansen P, Schnermann JB, Briggs JP. Influence of genetic background and gender on hypertension and renal failure in COX-2-deficient mice. Am J Physiol Renal Physiol. 2005;288(6):F1125-F1132.
24. Zhang M-Z, et al. CSF-1 signaling mediates recovery from acute kidney injury. J Clin Invest. 2012;122(12):4519-4532.
25. Hara S, Kamei D, Sasaki Y, Tanemoto A, Nakatani Y, Murakami M. Prostaglandin E synthases: understanding their pathophysiological roles through mouse genetic models. Biochimie. 2010;92(6):651-659.
26. Nataraj C, et al. Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. J Clin Invest. 2001;108(8):1229-1235.
27. - cotransporter by the WNK-regulated kinases SPAK and OSR1. J Cell Sci. 2008;121(pt 5):675-684.
28. Kopp C, et al. 23Na magnetic resonance imaging-determined tissue sodium in healthy subjects and hypertensive patients. Hypertension. 2013;61(3):635-640.
29. Kleinewietfeld M, et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature. 2013;496(7446):518-522.
30. Wu C, et al. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature. 2013;496(7446):513-517.
31. Hagendoorn J, et al. Endothelial nitric oxide synthase regulates microlymphatic flow via collecting lymphatics. Circ Res. 2004;95(2):204-209.
32. Kashiwagi S, Hosono K, Suzuki T, Takeda A, Uchinuma E, Majima M. Role of COX-2 in lym-phangiogenesis and restoration of lymphatic flow in secondary lymphedema. Lab Invest. 2011;91(9):1314-1325.
33. Johnson AG, Nguyen TV, Day RO. Do nonste-roidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121(4):289-300.
34. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest. 1994;94(6):2504-2510.
35. Yang T, et al. Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol. 1998;274(3 pt 2):F481-F489.
36. Catella-Lawson F, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999;289(2):735-741.
37. Rodriguez F, Llinas MT, Gonzalez JD, Rivera J, Salazar FJ. Renal changes induced by a cyclooxy-genase-2 inhibitor during normal and low sodium intake. Hypertension. 2000;36(2):276-281.
38. Qi Z, et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angio-tensin II. J Clin Invest. 2002;110(1):61-69.
39. Yao B, Harris RC, Zhang MZ. Interactions between 11beta-hydroxysteroid dehydrogenase and COX-2 in kidney. Am J Physiol Regul Integr Comp Physiol. 2005;288(6):R1767-R1773.
40. Zewde T, Mattson DL. Inhibition of cyclo-oxygenase-2 in the rat renal medulla leads to sodium-sensitive hypertension. Hypertension. 2004;44(4):424-428.
41. Sasaki Y, et al. Microsomal prostaglandin E syn-thase-1 is involved in multiple steps of colon car-cinogenesis. Oncogene. 2012;31(24):2943-2952.
42. Eruslanov E, Daurkin I, Ortiz J, Vieweg J, Kusmartsev S. Pivotal advance: tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE(2) catabolism in myeloid cells. J Leukoc Biol. 2010;88(5):839-848.
43. Takayama K, Garcia-Cardena G, Sukhova GK, Comander J, Gimbrone MA Jr, Libby P. Prosta-glandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem. 2002;277(46):44147-44154.
44. Rodriguez-Iturbe B, Pons H, Quiroz Y, Johnson RJ. The immunological basis of hypertension. Am J Hypertens. 2014;27(11):1327-1337.
45. Wenzel P, et al. Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. Circulation. 2011;124(12):1370-1381.
46. Elmarakby AA, et al. Chemokine receptor 2b inhibition provides renal protection in angio-tensin II - salt hypertension. Hypertension. 2007;50(6):1069-1076.
47. Chan CT, et al. Reversal of vascular macrophage accumulation and hypertension by a CCR2 antagonist in deoxycorticosterone/salt-treated mice. Hypertension. 2012;60(5):1207-1212.
48. Pires PW, Girgla SS, McClain JL, Kaminski NE, van Rooijen N, Dorrance AM. Improvement in middle cerebral artery structure and endothelial function in stroke-prone spontaneously hyper tensive rats after macrophage depletion. Micro circulation. 2013;20(7):650-661.
49. Zandbergen HR, et al. Macrophage depletion in hypertensive rats accelerates development of cardiomyopathy. J Cardiovasc Pharmacol Ther. 2009;14(1):68-75.
50. De Miguel C, Rudemiller NP, Abais JM, Mattson DL. Inflammation and hypertension: new understandings and potential therapeutic targets. Curr Hypertens Rep. 2015;17(1):507.
51. Kirabo A, et al. DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest. 2014;124(10):4642-4656.
52. Chen L, Zhu Y, Zhang G, Gao C, Zhong W, Zhang X. CD83-stimulated monocytes suppress T-cell immune responses through production of prostaglandin E2. Proc Natl Acad Sci USA. 2011;108(46):18778-18783.
53. + T lymphoblasts. J Immunol. 1995;154(3):1041-1047.
54. + T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. Cancer Res. 2008;68(18):7520-7529.
55. Pablos JL, Santiago B, Carreira PE, Galindo M, Gomez-Reino JJ. Cyclooxygenase-1 and -2 are expressed by human T cells. Clin Exp Immunol. 1999;115(1):86-90.
56. Ryan EP, Pollock SJ, Murant TI, Bernstein SH, Felgar RE, Phipps RP. Activated human B lymphocytes express cyclooxygenase-2 and cyclo-oxygenase inhibitors attenuate antibody production. J Immunol. 2005;174(5):2619-2626.
57. Subramanya AR, Ellison DH. Distal convoluted tubule. Clin J Am Soc Nephrol. 2014;9(12):2147-2163.
58. -/- mice. Hypertension. 2015;65(3):569-576.
59. + transporters along nephron during ANG II-dependent hypertension: distal stimulation counteracted by proximal inhibition. Am J Physiol Renal Physiol. 2013;305(4):F510-F519.
60. Jia Z, Aoyagi T, Kohan DE, Yang T. mPGES-1 deletion impairs aldosterone escape and enhances sodium appetite. Am J Physiol Renal Physiol. 2010;299(1):F155-F166.
61. Wiig H, et al. Immune cells control skin lymphatic electrolyte homeostasis and blood pressure. J Clin Invest. 2013;123(7):2803-2815.
62. Su JL, et al. Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarci-noma. Cancer Res. 2004;64(2):554-564.
63. Timoshenko AV, Chakraborty C, Wagner GF, Lala PK. COX-2-mediated stimulation of the lym-phangiogenic factor VEGF-C in human breast cancer. Br J Cancer. 2006;94(8):1154-1163.
64. Iwata C, et al. Inhibition of cyclooxygen-ase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res. 2007;67(21):10181-10189.
65. Hosono K, et al. Roles of prostaglandin E2-EP3/EP4 receptor signaling in the enhancement of lymphangiogenesis during fibroblast growth factor-2-induced granulation formation. Arterio-scler Thromb Vasc Biol. 2011;31(5):1049-1058.
66. Kashiwagi S, Hosono K, Suzuki T, Takeda A, Uchinuma E, Majima M. Role of COX-2 in lym-phangiogenesis and restoration of lymphatic flow in secondary lymphedema. Lab Invest. 2011;91(9):1314-1325.
67. Dinchuk JE, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature. 1995;378(6555):406-409.
68. Schneider A, et al. Generation of a conditional allele of the mouse prostaglandin EP4 receptor. Genesis. 2004;40(1):7-14.
69. Ferron M, Vacher J. Targeted expression of Cre recombinase in macrophages and osteoclasts in transgenic mice. Genesis. 2005;41(3):138-145.
70. Nishida M, et al. Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. J Clin Invest. 2002;110(12):1859-1868.
71. Yao B, Harris RC, Zhang MZ. Intrarenal dopa-mine attenuates deoxycorticosterone acetate/high salt-induced blood pressure elevation in part through activation of a medullary cyclooxygenase 2 pathway. Hypertension. 2009;54(5):1077-1083.
72. Zhang MZ, et al. Intrarenal dopamine deficiency leads to hypertension and decreased longevity in mice. J Clin Invest. 2011;121(7):2845-2854.
73. Leu AJ, Berk DA, Yuan F, Jain RK. Flow velocity in the superficial lymphatic network of the mouse tail. Am J Physiol. 1994;267(4 pt 2):H1507-H1513.
74. Zhang MZ, Yao B, Cheng HF, Wang SW, Inagami T, Harris RC. Renal cortical cyclooxygenase 2 expression is differentially regulated by angio-tensin II AT(1) and AT(2) receptors. Proc Natl Acad Sci USA. 2006;103(43):16045-16050.
75. Zhang MZ, et al. Role of epoxyeicosatrienoic acids (EETs) in mediation of dopamine's effects in the kidney. Am J Physiol Renal Physiol. 2013;305(12):F1680-F1686.
76. Zhang MZ, et al. Inhibition of 11beta-hydroxy-steroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans. J Clin Invest. 2009;119(4):876-885.